NTRK2 and depressive symptom measurement: In conclusion, fusion with the TXB4 module allows the TrkB agonist antibody to reach neuroprotective concentrations in the brain parenchyma following systemic administration, generating a new class of biologic with therapeutic potential in a wide range of neurodegenerative diseases, acute brain injury situations and possibly depression.